Novartis (NYSE: NVS) halted enrollment in a clinical trial of GenVec Inc.'s (Nasdaq: GNVC) CGF166 in order to review safety data. Shares of GenVec plummeted $1.03 to $0.70 while Novartis stock lost 61 cents to $80.95.
Enrollment in GenVec's CGF166 study halted
January 11, 2016 at 12:35 PM EST
